PBK expression predicts favorable survival in colorectal cancer patients
PBK expression predicts favorable survival in colorectal cancer patients
复制标题
DOI：
10.1007/s00428-021-03062-0
复制
发表时间：
2021-02-27
期刊：
影响因子：
3.5
通讯作者：
Takahashi, Satoru
中科院分区：
文献类型：
--
作者：
Nagano-Matsuo, Aya;Inoue, Satoshi;Takahashi, Satoru
结直肠癌（Colorectal cancer，CRC）是世界范围内最常见的胃肠道恶性肿瘤之一，发病率和死亡率都很高。小分子抗癌试剂的发现显著影响了癌症治疗。然而，这些疗法的抗癌作用不足以完全治愈CRC。PDZ结合激酶（PBK）最初被鉴定为丝裂原活化蛋白激酶的有丝分裂激酶，并参与胞质分裂和精子发生。已报道PI 3 K的异常表达与许多癌症的恶性表型和/或患者存活密切相关。然而，PI 3 K的表达及其与CRC患者生存期的关系尚未完全阐明。在本研究中，对269例原发性CRC进行了免疫组织化学评价，以评估其作为预后因素的能力。CRC肿瘤细胞在细胞核和细胞质中不表达PI 3 K（范围，0-100%;中值，32%）。单因素分析显示，PBK表达与pT分期呈显著负相关（P
Colorectal cancer (CRC) is one of the most common gastrointestinal cancers worldwide with high morbidity and mortality rates. The discovery of small molecule anticancer reagents has significantly affected cancer therapy. However, the anticancer effects of these therapies are not sufficient to completely cure CRC. PDZ-binding kinase (PBK) was initially identified as a mitotic kinase for mitogen-activated protein kinase and is involved in cytokinesis and spermatogenesis. Aberrant expression of PBK has been reported to be closely associated with malignant phenotypes of many cancers and/or patient survival. However, the expression of PBK and its association to patient survival in CRC have not been fully elucidated. In the present study, 269 primary CRCs were evaluated immunohistochemically for PBK expression to assess its ability as a prognostic factor. CRC tumor cells variably expressed PBK (range, 0-100%; median, 32%) in the nucleus and cytoplasm. Univariate analyses identified a significant inverse correlation between PBK expression and pT stage (P